Top Bulls Reasons To Buy — Vote below!

Add a New Bulls Reason

Company: Novartis AG (NVS)
Current price:
Headline: (100 character max)
Analysis:
Cancel
93%
agree
16 votes

  Alcon Acquisition

The acquisition from Nestle will add the world’s eye care leader to Novartis’ portfolio, much of which is focused on prescription drugs that are facing increased competition from generic drug manufacturers. Alcon’s eye care products range includes surgical, pharmaceutical and consumer products.

"This acquisition furthers our strategy of accessing high-growth segments of the healthcare market while balancing inherent risks. The strategic fit of Alcon and Novartis is excellent with our complementary product portfolios and R&D synergies. Eye care will continue to grow dynamically as there is a growing unmet medical need driven primarily by the world’s aging population," Dr. Daniel Vasella, Chairman and CEO of Novartis, said in a statement.

In the optional second step, it can acquire the remaining 52% for a fixed price of $181 per share (about $28 billion) between January 2010 and July 2011. Nestle has the right to require Novartis to buy its remaining Alcon stake.

(100 character max) Cancel
80%
agree
5 votes

  Novartis has strongest pipelines (50 new drugs in 5 years)

Novartis has one of the strongest pipelines in the pharmaceutical industry, and as many as 50 new medications could come through the pipeline in the next 5 years. Additionally, Tekturna, a hypertension medication, was recently approved by the FDA and will hit the market this year.

(100 character max) Cancel
100%
agree
2 votes

  Undervalued

The price of NVS stock has dropped – actually down almost 8% so far this year, with a P/E under 14. It pays a nice dividend near 4%. It’s earnings are still extremely healthy – at $3.31 a share. And it’s going to be one of the biggest winners when the healthcare bill gets passed. [1]
  1. InvestmentU article titled "Healthcare Truths"
(100 character max) Cancel
100%
agree
1 votes

  Diovan will remain under patent protection for another five years

Diovan will remain under patent protection for another five years. It currently makes up 20% of Novartis’ pharmaceutical revenue, and this blockbuster drug's sales are expected to increase in coming years.

(100 character max) Cancel
0%
agree
0 votes

  Multiple-sclerosis drug FTY720 to be launched

A new study showed that patients taking its experimental oral multiple-sclerosis drug FTY720 were more likely to go two years without seeing the disease flare up. Also, second late-stage trial on FTY720 showed that the drug significantly reduced the risk that patients suffer relapses or that their multiple sclerosis progresses. This paves the way for a possible launch as early as next year.

It has the potential to generate more than $1 billion in annual revenue. Marcus.tan.yi.wei 11:11, September 30, 2009 (PDT)

Reference

"Novartis MS Drug Points Toward 2010 Launch" Article from Wall Street Jounral

(100 character max) Cancel
0%
agree
1 votes

  Hexal and Eon acquisitions strengthens hold on generics

Novartis’ acquisition of Hexal and Eon Labs strengthens its hold on generic production. Their incorporation into the Sandoz division makes Novartis a true generic powerhouse. The purchase of the entirety of Chiron, a vaccine producer, both diversifies Novartis further and will allow them to capture a larger portion of the vaccine market.

(100 character max) Cancel
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki